IN8BIO INC. - COMMON STOCK

IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

12 8 2022 16:15:00 提供 Nasdaq GlobeNewswire

IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock

11 8 2022 22:05:00 提供 Nasdaq GlobeNewswire

IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients

27 7 2022 07:00:01 提供 Nasdaq GlobeNewswire

Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform

21 7 2022 07:00:01 提供 Nasdaq GlobeNewswire

IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development

12 7 2022 08:00:01 提供 Nasdaq GlobeNewswire

IN8bio to Present at July Investor and Scientific Conferences

30 6 2022 16:15:00 提供 Nasdaq GlobeNewswire

IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences

08 6 2022 08:00:01 提供 Nasdaq GlobeNewswire

IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022

06 6 2022 07:00:00 提供 Nasdaq GlobeNewswire

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

17 5 2022 07:00:02 提供 Nasdaq GlobeNewswire

IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

12 5 2022 08:00:02 提供 Nasdaq GlobeNewswire

IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting

05 5 2022 08:00:02 提供 Nasdaq GlobeNewswire

IN8bio to Present at May Investor and Scientific Conferences

04 5 2022 08:00:01 提供 Nasdaq GlobeNewswire

IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments

13 4 2022 08:30:00 提供 Nasdaq GlobeNewswire

IN8bio to Present at April Investor and Scientific Conferences

05 4 2022 16:15:00 提供 Nasdaq GlobeNewswire

IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

28 3 2022 08:00:01 提供 Nasdaq GlobeNewswire

IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

17 3 2022 16:15:00 提供 Nasdaq GlobeNewswire

IN8bio to present at March Investor and Scientific Conferences

04 3 2022 07:00:00 提供 Nasdaq GlobeNewswire

IN8bio to present at Bio CEO & Investor Conference and Next Generation CAR-TCR Summit

10 2 2022 17:36:28 提供 Nasdaq GlobeNewswire

IN8bio to Present at Upcoming January Investor Conferences

10 1 2022 07:00:04 提供 Nasdaq GlobeNewswire

IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme

06 1 2022 07:00:01 提供 Nasdaq GlobeNewswire